# Immune-Onc Therapeutics

**Canonical:** https://apis.io/providers/immune-onc-therapeutics/  
**Website:** https://www.immune-onc.com/  
**APIs profiled:** 0

Immune-Onc Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California, founded in 2016 by Charlene Liao and Guo Liang Yu. The company develops novel antibody therapeutics that target myeloid cell inhibitory receptors — with a current focus on the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB) — to treat blood cancers, solid tumors, and autoimmune and inflammatory disease. Its clinical pipeline includes IO-108, a fully human IgG4 antagonist antibody targeting LILRB2 (ILT4) in Phase 1b/2 for solid tumors including hepatocellular carcinoma, and IO-202, a first-in-class IgG1 antibody targeting LILRB4 (ILT3) in Phase 1b for acute myeloid leukemia and chronic myelomonocytic leukemia, which holds FDA Fast Track and Orphan Drug designations. Preclinical programs include IO-312, a LILRB4-directed bispecific antibody, and IO-106 targeting LAIR1. The company has clinical collaborations with BeiGene, Regeneron, and Roche, and has raised approximately $138 million across Series A and Series B financings from investors including Northern Light Venture Capital, Vivo Capital, CLI Ventures, and the Stanford-StartX Fund. Immune-Onc is a therapeutics developer, not a software or platform company: as of this profile it publishes no public API, developer portal, OpenAPI or other machine-readable contract, no SDKs, no public GitHub organization and no /.well-known/ discovery surface — its only machine-readable documents are two Squarespace RSS feeds for its news and press-release collections. This record therefore captures the company's verified public identity, its published web properties, its clinical-trial registry presence, and the probed security posture of its public web surface.

## Kin Score — 6.4 / 100 (minimal)

Scored 2026-08-17 under rubric 0.11.0. Trend: flat (+0.0 from 6.4).

| Facet | Score |
|---|---|
| Discoverability | 57.4 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 2.2 |
| Commercial Clarity | 0.0 |

Regulatory layer — **Health**: 7.5 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## Security (1)

- **Immune Onc Therapeutics Domain Security** — TLSv1.3 · DMARC

## Tags

Company, Biotechnology, Biopharmaceutical, Oncology, Immunotherapy, Immuno-Oncology, Antibodies, Clinical Trials, Life Sciences, Healthcare, Drug Development

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/immune-onc-therapeutics/). Scores are computed from the provider's own public artifacts under a published rubric.